Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
University of Illinois Cancer Center, Chicago, Illinois Indiana Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana University of Iowa Hospitals and Clinics, Iowa City, Iowa University of Minnesota, Minneapolis, Minnesota Ohio State University Comprehensive Cancer Center, Columbus, Ohio University of Wisconsin, Madison, Wisconsin